- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00486733
Study to Determine if Shock Wave Therapy Applied to Traumatic Wounds of the Extremity Improves Healing Time (CWI)
Prospective Randomized Trial of Standard Wound Care Versus Standard Wound Care Plus Shock Wave Therapy for Traumatic Wounds of the Extremity
Study Overview
Detailed Description
Timely return of combat wounded to functional lives and duty is imperative. Reliance upon traditional wound management principles is restrictive, and a treatment paradigm aimed at high-energy projectile contaminated wounds suits the requirements of our combat casualty care program. The nature of war wounds makes them unsuitable for conventional, saline-soaked-gauze dressings.
Extra-corporeal-shockwave-therapy (ESWT) has been used successfully for orthopedic soft tissue indications. Pilot studies indicate that ESWT enhances tissue healing through growth-factor release and neovascularization, with favorable safety profile and anti-bacterial effect, particularly in problematic wounds including fracture non-unions, post-traumatic wounds, and burns.
The need to improve the healing and quality-of-life of the combat wounded, the potential of this minimal-risk technology to improve healing of difficult-to-treat orthopedic/soft tissue injury and infection, as well as the combat casualty care experience of surgeons at WRAMC, dovetail uniquely to have our wounded soldiers and medical center play a pivotal role as the fundamental proving ground and primary beneficiary of this technology.
Comparison(s): Standard-of-care wound therapy compared to standard-of-care wound therapy + ESWT for extremity wounds with the aim of conducting a definitive critical analysis of the role of ESWT in improved treatment and outcomes of traumatic soft tissue injuries of the extremity.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Tiffany Felix, MS
- Phone Number: 251-300-7397
- Email: tfelix@hjfresearch.org
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20307
- Recruiting
- Walter Reed Army Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients should be 18 years of age or older, and capable of providing informed consent indicating awareness of the investigational nature of this trial, in keeping with institutional policy.
- Written informed consent must be obtained from each patient prior to entering the study.
- Female patients will not be pregnant. Exclusion of the possibility of pregnancy by HCG testing (urine or serum) or by history (tubal ligation, hysterectomy, or menopause) is required prior to inclusion in the study.
- Patients should be willing to be followed within the military healthcare system, or the participating civilian center during the course of study treatment and follow-up.
- Patients with traumatic wound(s) of the upper and/or lower extremity. The study wound is the wound with the highest Red Cross Wound Classification (RCWC).
- Patients should demonstrate adequacy of limb perfusion by all of the following clinical parameters in the affected extremity to be treated by investigational shock wave therapy: Palpable distal extremity pulse; Absence of compartment syndrome; or Ankle Brachial Index(ABI) ≥ 0.9 or transcutaneous pulse oximetry, tcP02≥20mmHg.
- Patients with non-circumferential, second degree burn wounds of the upper and/or lower extremity.
Exclusion Criteria:
- Patients with current participation in another clinical investigation of a medical device or a drug the requirements of which may preclude complete involvement in this study.
- Women who are pregnant.
- One or more of the following findings in the affected extremity to be treated by investigational shock wave therapy: Ankle Brachial Index < 0.9 or tcP02<20 mmHg; Significant arterial or venous injury requiring surgical intervention; or Lymphedema.
- Subject has another non-superficial wound near the study wound that is less than 3cm from the study wound or that has a RCWC of 3.
- Active or previous (within 60 days prior to the study screening visit) chemotherapy.
- Active or previous (within 60 days prior to the study screening visit) radiation to the affected extremity to be treated by investigational shock wave therapy.
- Physical or mental disability or geographical concerns (residence not within reasonable travel distance) that would hamper compliance with required study visits.
- The Investigator believes that the subject will be unwilling or unable to comply with study protocol requirements, including the shock wave treatment procedure, standard-of-care self-care requirements, and all study-related follow up visit requirements.
- Patients with 1st degree, 3rd degree, or circumferential extremity burns considered for treatment by investigational shock wave therapy.
- History of sickle cell anemia.
- History of infection with Human Immunodeficiency Virus.
- History of immunodeficiency disorders.
- Severe anemia - Hgb < 7 g/dl (males) or < 6.5 (females).
- Deep vein thrombosis within 6 months of study screening visit.
- Chronic renal insufficiency requiring dialysis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard of Care
Standard of Care Treatment; no study treatment
|
|
Experimental: Standard of Care plus Study Treatment
Standard of Care Treatment plus study treatment
|
The first four follow-up study assessment and data collection points will coincide with scheduled operative interventions on the wound guided by clinical situation and the treating physician's judgment (approximately every 3-4 days).
Subsequent follow-up study assessment and data collection points will occur on study days 28 ± 3, 42 ± 3, 60 ± 3, and 90 ± 3.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to complete wound healing. For purposes of this study, the definition of "healed" is wound closure with total epithelialization of the soft tissue defect, confirmed at two consecutive study visits.
Time Frame: 90 days following initial treatment
|
90 days following initial treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total number of study subjects with a final status of "healed" in the ESWT therapy group versus control group.
Time Frame: 90 days following initial treatment
|
90 days following initial treatment
|
The percentage of the soft tissue wound that has healed at 90 days as assessed by planimetric computerized digital measurement.
Time Frame: 90 days following intitial treatment
|
90 days following intitial treatment
|
The number of shock wave treatments performed.
Time Frame: Within six weeks following initial treatment
|
Within six weeks following initial treatment
|
For patients who have not achieved healed status at Day 90, the percent of wounds at Day 90 with lesser healing (≤50% epithelialization) versus with greater healing (>50% but < 100% epithelialization) as determined by planimetric CDM.
Time Frame: 90 days following initial treatment
|
90 days following initial treatment
|
Results of quantitative wound bacterial cultures (wounds with a quantitative wound bacterial count greater than 105 per gram of tissue will be defined as an "infected wound").
Time Frame: 28 days following inititial treatment
|
28 days following inititial treatment
|
Durability of wound closure (i.e., status of wound at one month following determination of "healed").
Time Frame: 90 days following initial treatment
|
90 days following initial treatment
|
Serial wound punch biopsies for quantitative bacterial cultures, bacterial 16sRNA, and molecular analysis of 185 relevant wound healing genes.
Time Frame: 28 days following intitial treatment
|
28 days following intitial treatment
|
Serum from venous blood and Vacuum Assisted Wound Closure Device (VAWCD) effluent for biomarkers, C-reactive protein, and cortisol levels.
Time Frame: 28 days following initial treatment
|
28 days following initial treatment
|
Mean wound surface area, circumference, depth and estimated volumes over time, ESWT group versus control group, as determined by CDM planimetry surface measurements.
Time Frame: 90 days following initial treatment
|
90 days following initial treatment
|
Length of hospital stay and number of surgical procedures for the extremity wound selected for study
Time Frame: 90 days following initial treatment
|
90 days following initial treatment
|
Assessment of relative burden of disease (trauma) between treatment groups by comparing mean values of the eight standard scales of the Medical Outcome Study 36-Item Short Form Health Survey (SF-36).
Time Frame: 90 days following intitial treatment
|
90 days following intitial treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Alexander Stojadinovic, MD, Walter Reed Army Medical Center
Publications and helpful links
General Publications
- Wang CJ. An overview of shock wave therapy in musculoskeletal disorders. Chang Gung Med J. 2003 Apr;26(4):220-32.
- Wang CJ, Chen HS, Chen CE, Yang KD. Treatment of nonunions of long bone fractures with shock waves. Clin Orthop Relat Res. 2001 Jun;(387):95-101. doi: 10.1097/00003086-200106000-00013.
- Meirer R, Kamelger FS, Huemer GM, Wanner S, Piza-Katzer H. Extracorporal shock wave may enhance skin flap survival in an animal model. Br J Plast Surg. 2005 Jan;58(1):53-7. doi: 10.1016/j.bjps.2004.04.027.
- Haupt G, Chvapil M. Effect of shock waves on the healing of partial-thickness wounds in piglets. J Surg Res. 1990 Jul;49(1):45-8. doi: 10.1016/0022-4804(90)90109-f.
- Schaden W, Fischer A, Sailler A. Extracorporeal shock wave therapy of nonunion or delayed osseous union. Clin Orthop Relat Res. 2001 Jun;(387):90-4. doi: 10.1097/00003086-200106000-00012.
- Ludwig J, Lauber S, Lauber HJ, Dreisilker U, Raedel R, Hotzinger H. High-energy shock wave treatment of femoral head necrosis in adults. Clin Orthop Relat Res. 2001 Jun;(387):119-26. doi: 10.1097/00003086-200106000-00016.
- Ludwig J, Lauber S, Lauber J, Hotzinger H. [Shockwave treatment of femur head necrosis in the adult]. Z Orthop Ihre Grenzgeb. 1999 Jul-Aug;137(4):Oa2-5. No abstract available. German.
- Lauber S. [High energy extracorporeal shockwave therapy in femur head necrosis]. Z Orthop Ihre Grenzgeb. 2000 Sep-Oct;138(5):Oa3-4. No abstract available. German.
- Gerdesmeyer L, von Eiff C, Horn C, Henne M, Roessner M, Diehl P, Gollwitzer H. Antibacterial effects of extracorporeal shock waves. Ultrasound Med Biol. 2005 Jan;31(1):115-9. doi: 10.1016/j.ultrasmedbio.2004.08.022.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06-20028
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Soft Tissue Injuries
-
Akron Children's HospitalTerminatedSoft Tissue InjuryUnited States
-
University of Mississippi Medical CenterTerminatedPediatric Extremity Fracture | Pediatric Extremity Soft Tissue InjuryUnited States
-
University Hospital, LinkoepingCompletedAchilles Tendon Rupture | Soft Tissue Injury | Tendon InjurySweden
-
Linkoeping UniversityUnknownAchilles Tendon Rupture | Soft Tissue Injury | Tendon InjurySweden
-
Bayside HealthNational Health and Medical Research Council, Australia; Monash UniversityCompletedTibial Fracture | Soft Tissue InjuryAustralia, Sweden, Chile, United States, Austria, India, Italy, Portugal, Czechia
-
NovartisCompletedAcute Blunt Soft Tissue Injuries/ContusionsUnited States
-
NovartisCompletedAcute Blunt Soft Tissue Injuries/ContusionsGermany
-
University of PittsburghUnited States Department of DefenseCompletedExtremity Injury | Muscle Injury | Soft Tissue Injury | Traumatic Injury | Tendon InjuryUnited States
-
University of PittsburghUnited States Naval Medical Center, San Diego; United States Naval Medical...WithdrawnExtremity Injury | Muscle Injury | Soft Tissue Injury | Traumatic Injury | Tendon InjuryUnited States
Clinical Trials on DermaGold
-
Hadassah Medical OrganizationUnknown